[Value of hematopoietic stem cell autotransplantation in the treatment of multiple myeloma: initial experience at the National Bone Marrow Transplantation Center and review of the literature]
- PMID: 11190737
[Value of hematopoietic stem cell autotransplantation in the treatment of multiple myeloma: initial experience at the National Bone Marrow Transplantation Center and review of the literature]
Abstract
Alkylating agents administered with predisone have been the standard therapy for myeloma over the lost three decades. Intensive treatment with autologous hematopoietic support has become the treatment of choice for multiple myeloma patients up to 60 years of age. From march 1999 to january 2000, seven patients with multiple myeloma (stage III) with a median age of 43 years (34-56) received an autologous stem cell transplantation. The myeloablative treatment regimen consisted of high-dose melphalan. All patients had sustained engraftment. The median duration of neutropenia (< 500/mm3) was 12 days (11-140) and the median duration of thrombocytopenia (< 20,000/mm3) was 13 days (11-110). One patient had a complete remission, one a very good partial remission, and 5 patients had a partial remission. With a median follow-up of 8 months (2-12), all patients are alive, without relapse.
Similar articles
-
Oral mucositis and outcomes of autologous hematopoietic stem-cell transplantation following high-dose melphalan conditioning for multiple myeloma.J Support Oncol. 2007 May;5(5):231-5. J Support Oncol. 2007. PMID: 17564153
-
Autologous stem cell transplantation in multiple myeloma: improved survival in nonsecretory multiple myeloma but lack of influence of age, status at transplant, previous treatment and conditioning regimen. A single-centre experience in 127 patients.Bone Marrow Transplant. 2003 Feb;31(3):163-70. doi: 10.1038/sj.bmt.1703818. Bone Marrow Transplant. 2003. PMID: 12621476
-
Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma.Bone Marrow Transplant. 2002 Sep;30(6):367-73. doi: 10.1038/sj.bmt.1703652. Bone Marrow Transplant. 2002. PMID: 12235521 Clinical Trial.
-
[Hematopoietic stem cell transplantation in multiple myeloma].Rev Invest Clin. 2005 Mar-Apr;57(2):305-13. Rev Invest Clin. 2005. PMID: 16524072 Review. Spanish.
-
The role of transplant in multiple myeloma.Clin Adv Hematol Oncol. 2005 Aug;3(8):604-6. Clin Adv Hematol Oncol. 2005. PMID: 16167043 Review. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical